The interferon-regulated host factor hnRNPA0 modulates HIV-1 production by interference with LTR activity, mRNA trafficking, and programmed ribosomal frameshifting.

HIV‑1 IFN-repressed genes (IRepGs) IFN-stimulated genes (ISGs) host dependency factors alternative splicing hnRNPA0 programmed ribosomal frameshifting (-1PRF) transcription type I interferons (IFN-I) viral replication

Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
20 Jun 2024
Historique:
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 20 6 2024
Statut: aheadofprint

Résumé

The interplay between host factors and viral components impacts viral replication efficiency profoundly. Members of the cellular heterogeneous nuclear ribonucleoprotein family (hnRNPs) have been extensively studied as HIV-1 host dependency factors, but whether they play a role in innate immunity is currently unknown. This study aimed to identify hnRNPA0 as a type I interferon (IFN)-repressed host factor in HIV-1-infected cells. Knockdown of hnRNPA0, a situation that mirrors conditions under IFN stimulation, increased LTR activity, export of unspliced HIV-1 mRNA, viral particle production, and thus, increased infectivity. Conversely, hnRNPA0 overexpression primarily reduced plasmid-driven and integrated HIV-1 long terminal repeat (LTR) activity, significantly decreasing total viral mRNA and protein levels. In addition, high levels of hnRNPA0 significantly reduced the HIV-1 programmed ribosomal frameshifting efficiency, resulting in a shift in the HIV-1 p55/p15 ratio. The HIV-1 alternative splice site usage remained largely unaffected by altered hnRNPA0 levels suggesting that the synergistic inhibition of the LTR activity and viral mRNA transcription, as well as impaired ribosomal frameshifting efficiency, are critical factors for efficient HIV-1 replication regulated by hnRNPA0. The pleiotropic dose-dependent effects under high or low hnRNPA0 levels were further confirmed in HIV-1-infected Jurkat cells. Finally, our study revealed that hnRNPA0 levels in PBMCs were lower in therapy-naive HIV-1-infected individuals compared to healthy controls. Our findings highlight a significant role for hnRNPA0 in HIV-1 replication and suggest that its IFN-I-regulated expression levels are critical for viral fitness allowing replication in an antiviral environment.IMPORTANCERNA-binding proteins, in particular, heterogeneous nuclear ribonucleoproteins (hnRNPs), have been extensively studied. Some act as host dependency factors for HIV-1 since they are involved in multiple cellular gene expression processes. Our study revealed hnRNPA0 as an IFN-regulated host factor, that is differently expressed after IFN-I treatment in HIV-1 target cells and lower expressed in therapy-naïve HIV-1-infected individuals. Our findings demonstrate the significant pleiotropic role of hnRNPA0 in viral replication: In high concentrations, hnRNPA0 limits viral replication by negatively regulating Tat-LTR transcription, retaining unspliced mRNA in the nucleus, and significantly impairing programmed ribosomal frameshifting. Low hnRNPA0 levels as observed in IFN-treated THP-1 cells, particularly facilitate HIV LTR activity and unspliced mRNA export, suggesting a role in innate immunity in favor of HIV replication. Understanding the mode of action between hnRNPA0 and HIV-1 gene expression might help to identify novel therapeutically strategies against HIV-1 and other viruses.

Identifiants

pubmed: 38899932
doi: 10.1128/jvi.00534-24
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0053424

Auteurs

Fabian Roesmann (F)

Goethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.

Helene Sertznig (H)

Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Katleen Klaassen (K)

Goethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.

Alexander Wilhelm (A)

Goethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.

Delia Heininger (D)

Goethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.

Stefanie Heß (S)

Goethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.

Carina Elsner (C)

Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Rolf Marschalek (R)

Institute of Pharmaceutical Biology, Goethe-University, Frankfurt am Main, Hessen, Germany.

Mario L Santiago (ML)

Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA.

Stefan Esser (S)

Institute for the Research on HIV and AIDS-associated Diseases University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Department of Dermatology, HPSTD Outpatient Clinic, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Kathrin Sutter (K)

Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Institute for the Research on HIV and AIDS-associated Diseases University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Ulf Dittmer (U)

Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Institute for the Research on HIV and AIDS-associated Diseases University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Marek Widera (M)

Goethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.

Classifications MeSH